There are many options in the treatment of heavily pretreated
metastatic breast cancer however none of the
therapeutic agents have shown promising improvement of
survival with good toxicity profile. Eribulin is a novel nontaxane
microtubule dynamics inhibitor. Two recent clinical
trial showed that Eribulin improves progression-free and
overall survival in this subset of patients. We report our
experience with using Eribulin in five patients with
metastatic breast cancer either in second or third-line
setting, in our centre.